New drug A-005 tested in healthy people for first time
NCT ID NCT07442149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the safety and how the body processes a new drug called A-005 in 135 healthy adults. Participants received either single or multiple doses of A-005 or a placebo. The goal was to check for side effects and measure drug levels in the blood and spinal fluid, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A-005
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion
Lincoln, Nebraska, 68502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New drug BIIB115 aims to build on gene therapy for spinal muscular atrophy
- Melt-in-Mouth migraine pill could make dosing easier
- Scientists test how body weight influences a new drug's absorption
- First human test of BIIB144 begins: safety first
- Antifungal drug may alter levels of experimental cancer pill